Eagle Pharmaceuticals,Inc. (NYSE:TEVA) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
In connection with the 2017 Annual Meeting of Stockholders of
Eagle Pharmaceuticals,Inc., or the Company, to be held on June20,
2017, the Company intends to mail its proxy materials to certain
stockholders and to post a copy of the Companys 2016 annual
report, which includes a 10-K wrap, or the 10-K Wrap, on or about
May 4, 2017.
A copy of the above-referenced 10-K Wrap is furnished as
Exhibit99.1 to this Current Report on Form8-K. The information
furnished to Item 7.01 of this current report, including
Exhibit99.1, shall not be deemed to be filed for the purposes of
Section18 of the Securities Exchange Act of 1934, as amended. As
such, this information shall not be incorporated by reference
into any of the Companys reports or other filings made with the
Securities and Exchange Commission. The furnishing of the
information in this current report is not intended to, and does
not, constitute a determination or admission by the Company that
the information in this current report is material or complete,
or that investors should consider this information before making
an investment decision with respect to any security of the
Company.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
ExhibitNo. |
|
Description |
|
99.1 |
10-K Wrap (to the Companys 2016 annual report) |
About Eagle Pharmaceuticals, Inc. (NYSE:TEVA)
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women’s health and selected other areas. Eagle Pharmaceuticals, Inc. (NYSE:TEVA) Recent Trading Information
Eagle Pharmaceuticals, Inc. (NYSE:TEVA) closed its last trading session down -0.15 at 31.58 with 5,028,911 shares trading hands.
